Skip to content Skip to main menu

Our Science

OUR MICROBIOME DETERMINES BALANCED HEALTH

MD Healthcare Precision Medicine Platform

MD Healthcare has cultivated a one-of-a-kind precision medicine platform founded on a unique convergence of biotechnology (BT), nanotechnology (NT), and information technology (IT). While most microbiome analysis focuses on who is there, we look at what they are doing systemically throughout our body via nano-meter sized extracellular vesicles. These nanoscopic particles released by all cells, including our bacteria, contain identifiable bacterial DNA as well as important immune modifying proteins and molecules.

As we continue to amass an expansive database of over 34,000 clinical samples of a wide variety of disease and sample types, we are developing four core precision medicine platforms based on Next-Generation Sequencing (NGS) and quantitative polymerase chain reaction (qPCR) technologies. This includes our Therapeutics (MD NanoDrone™), Diagnostics (MD NanoNavi™), precision Healthcare Navigation (MD Navi™), and Medical Food (MD FIT™) precision medicine platforms.


Therapeutic Platform: MD ICON



Innovative drug discovery platform (MD ICON) is a technology for identifying microbial extracellular vesicles and analyzing metagenomic big data using an automatic AI system. Our innovative microbial EV, big data, and AI analysis convergence technology led us to develop a one-of-a-kind drug discovery platform that enables fast and simple drug discovery.

We overcame high costs, long term, difficulties in screening innovative drug discovery technologies, and difficulties in screening candidate strains through fungus-based fecal samples. Through MD ICON, the unmet demand for the development of new generations of treatments is resolved.

Therapeutic Platform: MD NanoDrone™

Our innovative microbiome, EV, and bioinformatics convergence technology led us to develop an one-of-a-kind drug development platform that enables fast, simple drug discovery. Furthermore, our therapeutic platform has the distinct advantage of no need for lead optimization since microbial EVs can be efficiently manufactured through natural bacterial cultivation. Microbial EVs naturally exist in our bodies and thorough testing and screening has shown no toxicity in vivo.
Finally, by combining microbial EVs with microbiome bioinformatic information, we can develop not only disease treatment, but also preventative therapeutic options to reduce risk prior to disease onset.


For more information on our therapeutic solutions currently in development, visit our Therapeutic Pipeline page.


MD NanoDrone™

  • Metagenomics
  • Bioinformatics
  • Culture & EV Isolation
  • In vitro Screening
  • None
  • Cellular Disease Models
  • Mechanism of Action(MOA)
  • Animal Models of Disease States
  • ADME imaging
  • Toxicology
  • Clinical Trials & Therapeutics

Conventional Platforms

  • Cellular & Genetic Targets
  • Genomics
  • Proteomics
  • Bioinformatics
  • Synthesis & Isolation
  • Combinatorial Chemistry
  • Assay Development
  • In vitro screening
  • Library Development
  • Structure Activity Studies
  • In Siloco Screening
  • Chemical Synthesis
  • Drug Affinity & Selectivity
  • Cellular Disease Models
  • Lead Candidate Refinement
  • Mechanism of Action
  • Animal Models of Disease States
  • ADME
  • Toxicology
  • Clinical Trials & Therapeutics

Diagnostic Platform: MD NanoNavi™

Our innovative microbiome, extracellular vesicles (EV), and bioinformatics convergence technology enabled us to develop a one-of-a-kind diagnostic platform capable of non-invasive and accurate diagnosis of chronic illness including cancer and more. By targeting microbial EVs associated with the microbiome that comprises over 99% of the genes in our body, our diagnostic platform utilizes EV biomarkers with enormous diagnostic potential. As microbial EVs exist systemically throughout our body rather than primarily residing in the gut like bacteria, we can perform diagnosis on a wide array of clinical samples including stool, urine, blood, and saliva using our unique EV isolation methodology. We currently are developing a range of diagnostic products that include an EV DNA extraction kit in addition to a quantitative polymerase chain reaction (qPCR) and Next-Generation Sequencing (NGS) products with associated software (SW) packages.


For more information on our diagnostic solutions currently in development, visit our Diagnostic Pipeline page.


Personal Healthcare Navigation: MD Navi™

The main goal of our precision medicine platforms is to use the complex information contained in the thousands of different bacterial EVs in your body to guide you towards a healthier microbiome balance with straightforward, personalized healthcare navigation. Imbalanced microbiome activity has been associated with dozens of different chronic illnesses including cancers, cardiovascular disease, and cognitive disorders. Based on the analysis of over 34,000 patient samples, we developed a powerful algorithm using machine learning to determine your microbiome-associated disease risk in addition to dietary changes you can make to reduce disease risk and promote health.


For more information on our personal Healthcare Navigation service, visit our MD Navi™ homepage.